{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:02:31Z","timestamp":1793390551368,"version":"4.5.0"},"reference-count":22,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T00:00:00Z","timestamp":1559779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Brain and Behavior"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Determination of antibodies against the John Cunningham virus (JCV) is an important tool for risk stratification in Natalizumab\u2010treated multiple sclerosis (MS) patients. Six\u2010monthly testing has been suggested for anti\u2010JCV antibody negative patients and patients with low antibody index in order to detect changes of serostatus. We conducted a prospective study with predefined testing intervals in order to investigate the predictability of anti\u2010JCV antibody status and the intervals for repetitive testing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Our study included 109 patients at the MS Clinic of the Departments of Neurology, Medical Universities of Innsbruck and Salzburg. Blood withdrawals were performed at five time points: baseline, month 1, 3, 6, and 12. Patients\u2019 sera were sent to Unilabs, Copenhagen, Denmark, where anti\u2010JCV antibodies were tested by a two\u2010step enzyme\u2010linked immunosorbent assay. Qualitative (negative\/positive) and quantitative results (anti\u2010JCV antibody index) were used for statistical analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In our cohort, 52.3% of the patients were positive for anti\u2010JCV antibodies at baseline, with a significant correlation with age, but no association with sex or prior disease\u2010modifying therapy. Seven patients converted and reverted from negative to positive status and vice versa around the cut\u2010off index of 0.4, but no patient showed a permanent seroconversion from negative to highly positive anti\u2010JCV antibody status.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Long\u2010term anti\u2010JCV antibody status, including seroconverters\/\u2010reverters around the cut\u2010off index, is highly predictable by testing three times within short intervals, however, we cannot suggest clearly defined intervals for repetitive testing. The rate of real seroconverters, i.e., new infections with JCV, per year seems lower than previously described.<\/jats:p><\/jats:sec>","DOI":"10.1002\/brb3.1332","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T07:18:56Z","timestamp":1559805536000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Conversion and reversion of anti\u2010John Cunningham virus antibody serostatus: A prospective study"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5117-4225","authenticated-orcid":false,"given":"Michael","family":"Auer","sequence":"first","affiliation":[{"name":"Department of Neurology Medical University of Innsbruck Innsbruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Hegen","sequence":"additional","affiliation":[{"name":"Department of Neurology Medical University of Innsbruck Innsbruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Sellner","sequence":"additional","affiliation":[{"name":"Department of Neurology Christian Doppler Medical Center, Paracelsus Medical University Salzburg Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Oppermann","sequence":"additional","affiliation":[{"name":"Department of Neurology Christian Doppler Medical Center, Paracelsus Medical University Salzburg Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Bsteh","sequence":"additional","affiliation":[{"name":"Department of Neurology Medical University of Innsbruck Innsbruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Di Pauli","sequence":"additional","affiliation":[{"name":"Department of Neurology Medical University of Innsbruck Innsbruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berger","sequence":"additional","affiliation":[{"name":"Department of Neurology Medical University of Innsbruck Innsbruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Deisenhammer","sequence":"additional","affiliation":[{"name":"Department of Neurology Medical University of Innsbruck Innsbruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,6,6]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2015.11.044"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-016-0427-6"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107829"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12304"},{"key":"e_1_2_8_6_1","first-page":"E25","article-title":"Four\u2010year longitudinal index stability data from stratify\u20102 support the clinical utility of index for risk stratification of natalizumab\u2010associated progressive multifocal leukoencephalopathy","volume":"87","author":"Campagnolo D.","year":"2016","journal-title":"Neurology"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1212\/WNL.86.16_supplement.P3.093","article-title":"An evaluation of the longitudinal stability of anti\u2010JC virus (JCV) antibody levels in patients with multiple sclerosis (MS)","volume":"86","author":"Donovan E.","year":"2016","journal-title":"Neurology"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174005"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30282-X"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000029"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2013.02.002"},{"key":"e_1_2_8_12_1","first-page":"117","article-title":"Stratification and monitoring of natalizumab\u2010associated progressive multifocal leukoencephalopathy risk: Recommendations from an expert group","volume":"87","author":"McGuigan C.","year":"2016","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2015.296"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513477925"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6487-5"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24286"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22366"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01342.x"},{"issue":"5","key":"e_1_2_8_19_1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/1352458517728814","article-title":"Anti\u2010JCV serology during natalizumab treatment: Review and meta\u2010analysis of 17 independent patient cohorts analyzing anti\u2010John Cunningham polyoma virus sero\u2010conversion rates under natalizumab treatment and differences between technical and biological sero\u2010converters","volume":"24","author":"Schwab N.","year":"2017","journal-title":"Multiple Sclerosis"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000195"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12988"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511429955"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-304332"}],"container-title":["Brain and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbrb3.1332","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/brb3.1332","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/brb3.1332","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/brb3.1332","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T06:27:21Z","timestamp":1721370441000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/brb3.1332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,6]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1002\/brb3.1332"],"URL":"https:\/\/doi.org\/10.1002\/brb3.1332","archive":["Portico"],"relation":{},"ISSN":["2162-3279","2162-3279"],"issn-type":[{"value":"2162-3279","type":"print"},{"value":"2162-3279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,6]]},"assertion":[{"value":"2019-01-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01332"}}